Index

A
Acute demyelinating syndrome, 31
Adolescent obesity, 94, 97
Amyloid fibrils, 221, 222, 224–230
Androgen, 42, 43
Antigen presentation, 16
  antigen-binding groove, 16
  T cells, 16, 17
Anti-inflammatory, 222, 223
Axon loss, 71, 72, 74, 77, 78

B
B-cell, 41, 45–47
Biobank, 186, 188, 189
Biomarker, 179–182, 185–187, 189
Blood brain barrier, 32, 33, 35–37, 40
Brain atrophy, 69, 77

C
Chronic-relapsing EAE, 143
Class I HLA, 2
  DRB1, 2
  DRB3, 2
  DRB4, 2
  DRB5, 2
  HLA-A, 2
  HLA-B, 2
  HLA-C, 2
  HLA-DP, 2
  HLA-DQ, 2
  HLA-DR, 2
CNS demyelinating disease, 147
Cognitive decline, 69, 70
Correlations between clinical phenotypes
  and HLA, 7
  age at onset of MS, 7
  brainstem and cerebellar lesions, 14
  clinical course of MS, 8
  cognitive function, 11
  cognitive impairment, 14
  magnetic resonance imaging (MRI), 11, 12
  oligoclonal immunoglobulin G (IgG) bands, 14
  primary progressive MS (PP-MS), 8–11
  response to treatment, 15
  severity of MS, 11, 12
  sites of lesion development, 13
Cortical lesions, 74

D
Demyelination, 75, 76
Diet, 67
Diffusion-weighted imaging, 73

E
EAE variants, 143
Environmental factors, 59, 63, 66
Epstein Barr virus, 63
Epstein–Barr virus infection, 89
Estrogen, 44, 45
Experimental autoimmune encephalomyelitis (EAE), 33–44, 46–48, 143, 199
Exposure to tobacco smoke, 91, 92

G
Gadolinium-enhancing lesions, 32, 72
Gene–environment interactions, 96
Genetic, 34, 47, 48
Genetic risk factors, 98
Gonadotrophins, 32, 45

H
HLA-DRB1, 89, 97
Human leucocyte antigen (HLA), 2, 3
  class I, class II, 2
  DNA genotyping, 2
  generic names, 2
  haplotype, 3
heterogeneity, 3
major histocompatibility (MHC), 2
nomenclature, 2
polymorphic, 3
serological names, 2
Hygiene hypothesis, 196

I
Immune suppression, 118, 123, 124, 127–130
tolerance, 124, 126
Immunosuppression, 128, 228
Killer immunoglobulin-like receptors, 18
class I HLA ligands, 18
on NK cells, 18

L
Late-onset MS, 31
Lifestyle/environmental risk factors, 97

M
Magnetic resonance imaging, 32
Menarche, 31, 32
Microglia, 35, 36, 40
Molecular chaperone, 223, 225, 226
Mononucleosis, 97
MS model, 148
MS progression, 69
MS susceptibility, 4, 6
caucasian populations, 4
class I HLA, 6
class II HLA, 6
HLA-DP, 6
HLA-DQ, 5
HLA-DRB1*15:01, 4
other ethnic backgrounds, 4
susceptibility haplotype, 5
Multiple sclerosis, 89, 90, 105–113, 221
Myelin oligodendrocyte glycoprotein
(MOG), 143

N
Necator americanus, 197, 205
Networks, 186, 189
Neurodegeneration, 223
Neurodegenerative disease, 144
Neurofilaments, 179, 180, 182, 183, 185, 186, 189
Neuroinflammation, 167
NOD/Lt mouse strain, 146

O
Obesity, 66, 67
Oral contraceptive use, 68

P
Parity, 67, 68
Pediatric-onset MS, 31
Prolactin, 46, 47
Puberty, 31, 32

Q
Qualification, 179, 181, 182, 189

R
Regulatory cells, 117, 120, 124, 126, 127
immunoregulatory myeloid cells, 123
mast cells, 128
regulatory B cells, 120, 123, 129
regulatory DC, 127, 128
regulatory T cells, 120, 123, 126
Relapse rate, 33, 41, 45, 46
Remyelination, 71, 75, 76
Rodent models, 75, 77

S
Self-assembling peptides, 230
Sex chromosomes, 47, 48, 77, 78
Sex hormones, 77, 78
Sex ratio, 59, 60, 62, 64, 66
Smoking, 65
Soluble HLA molecules, 17
produced by alternative splicing, 18
regulatory roles, 17
Spatio-temporal lesion mapping, 158
Sun exposure habits, 87, 88
Sunlight, 117–121, 126, 130
far-red/near-infrared wavelengths, 118
regulatory T cells, 121
ultraviolet radiation (UVR), 119
ultraviolet (UV), 120, 121
UVA, 118
UVB, 120

T
T helper cell, 33, 43
Th1, 35, 36, 38, 39, 44
Th17, 35, 36, 38, 39, 43, 44
T regulatory cells, 35
Trichiuris suis, 205
### Index

*Trichuris trichiura*, 197  
T1-weighted hypointense lesions, 73  
T2-weighted lesions, 72  

**U**  
Urbanization, 67, 68  

**V**  
Validation, 179, 180, 182, 186  
Vitamin D, 65, 66, 105–113  
Vitamin D deficiency, 87, 88, 90